CU20210081A7 - Composición de partículas de arn lipoplejo - Google Patents

Composición de partículas de arn lipoplejo

Info

Publication number
CU20210081A7
CU20210081A7 CU2021000081A CU20210081A CU20210081A7 CU 20210081 A7 CU20210081 A7 CU 20210081A7 CU 2021000081 A CU2021000081 A CU 2021000081A CU 20210081 A CU20210081 A CU 20210081A CU 20210081 A7 CU20210081 A7 CU 20210081A7
Authority
CU
Cuba
Prior art keywords
composition
rna particles
lipoplex
percent
concentration
Prior art date
Application number
CU2021000081A
Other languages
English (en)
Inventor
Heinrich Haas
Thomas Michael Hiller
Sebastian Hörner
Original Assignee
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNTech SE filed Critical BioNTech SE
Publication of CU20210081A7 publication Critical patent/CU20210081A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>La presente solicitud se refiere a una composición que comprende partículas de ARN lipoplejo que comprenden ARN y un lípido catiónico y un lípido adicional, cloruro de sodio a una concentración de 10 mM o menos, un estabilizador a una concentración del 10 porciento en peso por porcentaje en volumen ( porciento p/v) o menos, y un búfer.</p>
CU2021000081A 2019-04-05 2020-04-01 Composición de partículas de arn lipoplejo CU20210081A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2019/058635 WO2020200472A1 (en) 2019-04-05 2019-04-05 Preparation and storage of liposomal rna formulations suitable for therapy
PCT/EP2020/059308 WO2020201383A1 (en) 2019-04-05 2020-04-01 Preparation and storage of liposomal rna formulations suitable for therapy

Publications (1)

Publication Number Publication Date
CU20210081A7 true CU20210081A7 (es) 2022-05-11

Family

ID=66223673

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2021000081A CU20210081A7 (es) 2019-04-05 2020-04-01 Composición de partículas de arn lipoplejo

Country Status (16)

Country Link
US (1) US20220143069A1 (es)
EP (1) EP3946255A1 (es)
JP (1) JP2022527830A (es)
KR (1) KR20210148162A (es)
CN (1) CN113924082A (es)
AU (1) AU2020255262A1 (es)
BR (1) BR112021020011A2 (es)
CA (1) CA3134211A1 (es)
CL (1) CL2021002557A1 (es)
CO (1) CO2021013376A2 (es)
CU (1) CU20210081A7 (es)
IL (1) IL285811A (es)
MX (1) MX2021012138A (es)
SG (1) SG11202109164WA (es)
WO (2) WO2020200472A1 (es)
ZA (1) ZA202106237B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202228727A (zh) * 2020-10-01 2022-08-01 德商拜恩迪克公司 適用於治療之微脂體ｒｎａ調配物之製備及儲存
CA3200234A1 (en) 2020-11-25 2022-06-02 Daryl C. Drummond Lipid nanoparticles for delivery of nucleic acids, and related methods of use
WO2023148277A1 (en) 2022-02-02 2023-08-10 BioNTech SE Agents and methods for targeted delivery of nucleic acids to cells
WO2023148276A1 (en) 2022-02-02 2023-08-10 BioNTech SE Agents and methods for targeted delivery to cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0917891A2 (pt) 2008-08-25 2015-11-24 Amplimmune Inc antagonistas de pd-1 e métodos de utilização dos mesmos
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
US20110319473A1 (en) * 2010-06-29 2011-12-29 Surmodics, Inc. Compositions and methods for enhancement of nucleic acid delivery
CA2852064A1 (en) * 2011-10-14 2013-04-18 Stc.Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof
PL3427723T3 (pl) * 2012-03-26 2021-01-11 Biontech Rna Pharmaceuticals Gmbh Preparat rna do immunoterapii
WO2013143555A1 (en) * 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
CA3078292A1 (en) * 2017-10-20 2019-04-25 Biontech Rna Pharmaceuticals Gmbh Preparation and storage of liposomal rna formulations suitable for therapy

Also Published As

Publication number Publication date
WO2020201383A1 (en) 2020-10-08
KR20210148162A (ko) 2021-12-07
CL2021002557A1 (es) 2022-05-20
IL285811A (en) 2021-10-31
EP3946255A1 (en) 2022-02-09
AU2020255262A1 (en) 2021-09-23
CA3134211A1 (en) 2020-10-08
SG11202109164WA (en) 2021-10-28
MX2021012138A (es) 2021-11-03
CN113924082A (zh) 2022-01-11
CO2021013376A2 (es) 2021-10-20
JP2022527830A (ja) 2022-06-06
US20220143069A1 (en) 2022-05-12
WO2020200472A1 (en) 2020-10-08
BR112021020011A2 (pt) 2021-12-14
ZA202106237B (en) 2023-06-28

Similar Documents

Publication Publication Date Title
CU20210081A7 (es) Composición de partículas de arn lipoplejo
AR127361A2 (es) Composición farmacéutica de partículas de lipoplejos y arn, composición acuosa y método de preparación
AR122746A2 (es) Una formulación farmacéutica líquida estable de anticuerpo
CY1123657T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
IN2015MU00865A (es)
AR094583A1 (es) Composiciones que incluyen agentes para conferir carácter hidrofóbico y estabilizante y métodos para elaborar y usar los mismos
CO2017009083A2 (es) Arni dirigido a la proteína hungtingtina, partículas víricas que lo contienen y métodos para reducir la toxicicidad del arni
BR112022011956A2 (pt) Composições de concentrado de suspensão de diamida
PE20131324A1 (es) Formulacion subcutanea de anticuerpo anti-her2
AR088380A1 (es) Formulaciones de etanercept estabilizadas con cloruro de sodio
PE20150964A1 (es) Formulaciones acuosas estables de adalimumab
CL2019002478A1 (es) Formulación de anticuerpo monoclonal anti-vrs.
PE20212265A1 (es) Bioconjugados de antigenos-polisacaridos de e. coli, metodos de produccion y metodos de utilizacion de los mismos
AR070356A1 (es) Producto para cuidado oral y metodos de uso del mismo
MX2021002935A (es) Formulacion de anticuerpos contra csf-1r.
CU20190015A7 (es) Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden
MX2019000898A (es) Amortiguador de lavado de cromatografia de afinidad.
CL2009000573A1 (es) Composicion farmaceutica inyectable intraocular en forma de suspension acuosa que no contiene preservante, que consiste de acetonido de triamcinolona, carboximetilcelulosa de sodio, 0,002-0,02% de polisorbato 80, cloruros para ajustar la tonicidad, agente tamponante, agua y agente de ajuste de ph; uso para tratar el ojo.
BR212017022025U2 (pt) etiqueta de exibição para pecuária
BR112021017890A2 (pt) Composição líquida compreendendo um anticorpo do receptor alfa de interleucina-4 humana
AR092691A1 (es) Composicion farmaceutica que comprende rebamipida
ECSP20032084A (es) Formulaciones de composiciones de vacuna contra el virus del dengue
CY1116266T1 (el) Σταθερα αλατα της s-αδενοσυλμεθειονινης και μεθοδος παρασκευης τους
WO2019027221A3 (ko) pH 민감성 성분의 안정화용 조성물
PE20070840A1 (es) Composiciones que comprenden enzimas para reducir el estres inmunologico